Anakinra, the IL-1 receptor antagonist, and canakinumab, the anti-IL-1β neutralization antibody, have shown improvement of retinal vasculitis lesions and uveitis flares with reduced steroid dosage in Behçet’s disease–related uveitis [67]. This evidence concerns the gene IL1B and uveitis.